Pfizer announced July 11th that the company will be restructuring into three businesses effective as of the beginning of the 2019 fiscal year.

The company will be separating operations into Innovative Medicines, Established Medicines, and Consumer Healthcare businesses.” As we transition to a period post-2020 where we expect a higher and more sustained revenue growth profile we see this new structure better positioning each business to achieve its growth potential,” said Pfizer Chairman and CEO Ian Read.

Read the full press release from Pfizer here.